Open AccessAcute lung injury following the use of granulocyte-macrophage colony-stimulating factor
Author(s) -
Kristina Kudlak,
Jonas P. DeMuro,
Adel Hanna,
Harold Brem
Publication year - 2013
Publication title -
international journal of critical illness and injury science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.274
H-Index - 12
eISSN - 2231-5004
pISSN - 2229-5151
DOI - 10.4103/2229-5151.124168
Subject(s) - medicine , granulocyte macrophage colony stimulating factor , immunology , pathogenesis , lung , haematopoiesis , granulocyte , hematopoietic growth factor , macrophage , priming (agriculture) , immune system , granulocyte macrophage colony stimulating factor receptor , granulocyte colony stimulating factor , colony stimulating factor , macrophage colony stimulating factor , cytokine , stem cell , biology , biochemistry , botany , germination , chemotherapy , in vitro , genetics
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor with immunostimulatory effects that include the activation and priming of neutrophils. Neutrophils are an important part of the human immune system, yet they have been implicated in the pathogenesis of acute lung injury (ALI). GM-CSF has been found to increase the amount of activated neutrophils recruited to the lung tissue as well as to increase the life span of neutrophils leading to substantial lung tissue injury and the development of ALI. While, there have been few cases reported of ALI following GM-CSF, the experience reported here is the first of ALI subsequent to local administration of GM-CSF in a patient with significant pulmonary comorbidities.